Final Overall Survival Analysis of Monarch 2: A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

被引：9
|
作者：
Llombart-Cussac, Antonio
Sledge, George
Toi, Masakazu
Neven, Patrick
Sohn, Joo Hyuk
Inoue, Kenichi
Pivot, Xavier
Okera, Meena
Masuda, Norikazu
Kaufman, Peter A.
Koh, Han
Grischke, Eva-Maria
Conte, PierFranco
Andre, Valerie
Bian, Yuanyuan
Shahir, Ashwin
van Hal, Gertjan
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD13-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD13-11
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Herrscher, Hugo
    Velten, Michel
    Leblanc, Julie
    Kalish-Weindling, Michal
    Fischbach, Cathie
    Exinger, Delphine
    Pivot, Xavier
    Petit, Thierry
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376
  • [22] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Baselga, Jose
    Im, Seock-Ah
    Iwata, Hiroji
    Cortes, Javier
    De laurentiis, Michele
    Jiang, Zefei
    Arteaga, Carlos L.
    Jonat, Walter
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Takahashi, Masato
    Vuylsteke, Peter
    Hachemi, Soulef
    Dharan, Bharani
    Di Tomaso, Emmanuelle
    Urban, Patrick
    Massacesi, Cristian
    Campone, Mario
    LANCET ONCOLOGY, 2017, 18 (07): : 904 - 916
  • [23] Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial
    Gerratana, Lorenzo
    Kocherginsky, Masha
    Davis, Andrew A.
    D'Amico, Paolo
    Reduzzi, Carolina
    Puglisi, Fabio
    Cristofanilli, Massimo
    ONCOLOGIST, 2024, 29 (02): : 123 - 131
  • [24] Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
    Liu, Qi
    Hou, Lingli
    Zhao, Ying
    Yang, Hongwei
    Mo, Zhengying
    Yu, Fei
    CLINICS, 2023, 78
  • [25] A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.
    Yee, Douglas
    LoRusso, Patricia
    Sablin, Marie Paule
    Prat, Aleix
    Stradella, Agostina
    Utriainen, Meri
    Oliveira, Mafalda
    Yonemori, Kan
    Naito, Yoichi
    Hardebeck, Molly Catherine
    Puig, Marta
    Hu, Joy
    Biyukov, Tsvetan Nikolov
    Iwata, Hiroji
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis
    Burris, H. A.
    Chan, A.
    Im, S-A
    Chia, S.
    Tripathy, D.
    Esteva, F. J.
    Campone, M.
    Bardia, A.
    Kong, O.
    Bao, W.
    Diaz-Padilla, I.
    Lorenc, K. Rodriguez
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [28] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Toi, Masakazu
    Huang, Chiun-Sheng
    Im, Young-Hyuck
    Sohn, Joohyuk
    Zhang, Wei
    Sakaguchi, Sachi
    Haddad, Nadine
    van Hal, Gertjan
    Sledge Jr, George W.
    CANCER SCIENCE, 2023, 114 (01) : 221 - 226
  • [29] A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer
    Cescon, David W.
    Hilton, John
    Morales Murilo, Serafin
    Layman, Rachel M.
    Pluard, Timothy
    Yeo, Belinda
    Park, In Hae
    Provencher, Louise
    Kim, Sung-Bae
    Im, Young-Hyuck
    Wyce, Anastasia
    Krishnatry, Anu Shilpa
    Hicks, Kirsty
    Zhang, Qu
    Barbash, Olena
    Khaled, Ahmed
    Horner, Thierry
    Dhar, Arindam
    Oliveira, Mafalda
    Sparano, Joseph A.
    CLINICAL CANCER RESEARCH, 2024, 30 (02) : 334 - 343
  • [30] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Huang, C-S.
    Toi, M.
    Im, Y-H.
    Iwata, H.
    Sohn, J.
    Wang, H-C.
    Masuda, N.
    Im, S-A.
    Lu, Y.
    Haddad, N.
    Sakaguchi, S.
    Hurt, K.
    Neven, P.
    Llombart-Cussac, A.
    Sledge, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1259
12345